USPTO trademark

NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES

RegisteredUSPTOWord markClass 42

"NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES" is a word mark owned by Angiex, Inc., filed at the USPTO on March 4, 2022. It is registered and covers class 42 (Computer and Scientific Services).

Get this data via the API
Official USPTO record
NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES trademark as filed
As filed with the USPTO
Status
Registered
Since May 23, 2023
Filed
March 4, 2022
Registered
May 23, 2023
Expires
Not recorded
Application no.
97296549
Registration no.
7064074
Office
USPTO
United States Patent and Trademark Office
Mark type
Word mark
1 class
Ownership

Who owns NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES

The owner and representative on file with the office.

Owner

Angiex, Inc.

Cambridge, United States

Representative

Chelsea E. Carbone

Wilson Sonsini Goodrich & Rosati

Goods and services

What the mark covers

The products and services NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES is filed for, grouped by Nice class.

  • Scientific research and development in the fields of cancer, immunological-inflammatory conditions, tissue repair, eye diseases, cardiovascular disease, biology, laboratory testing, biotechnology, biochemistry, and medicine; research and product development services for others in the fields of cancer, immunological-inflammatory conditions, tissue repair, eye diseases, cardiovascular disease, biology, laboratory testing, biotechnology, biochemistry, and medicine; Medical and scientific research in the fields of cancer, immunological-inflammatory conditions, tissue repair, eye diseases, and cardiovascular disease detection; Providing information on the subject of scientific research in the fields of cancer, immunological-inflammatory conditions, tissue repair, eye diseases, cardiovascular disease, biology, laboratory testing, biotechnology, biochemistry, and medicine

History

What has happened so far

Steps recorded by the USPTO, newest first.

  1. Notice of registration confirmation emailed
  2. Registered-supplemental register
  3. Applicant/correspondence changes (non-responsive) entered
  4. Teas change of correspondence received
  5. Teas withdrawal of attorney received-firm retains
  6. Attorney/dom.rep.revoked and/or appointed
  7. Teas revoke/app/change addr of atty/dom rep received
  8. Teas change of owner address received
  9. Law office publication review completed
  10. Assigned to lie

10 earlier steps on the official record.

FAQ

About NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES

Who owns the trademark "NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES"?

The USPTO trademark "NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES" (application 97296549) is owned by Angiex, Inc.

What is the status of "NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES"?

Its status at the USPTO is: registered.

When was "NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES" registered?

It was registered on May 23, 2023.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

Get API keyView docs
GET /v1/trademarks/{id}
ID=tm_019d2a46-6a52-70a3-9deb-2736f3a5fd4e
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_019d2a46-6a52-70a3-9deb-2736f3a5fd4e",
  "object": "trademark",
  "mark_text": "NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES",
  "status": {
    "primary": "active",
    "stage": "registered"
  },
  "office_code": "US",
  "application_number": "97296549",
  "filing_date": "2022-03-04",
  "nice_classes": [
    42
  ],
  "owners": [
    {
      "name": "Angiex, Inc.",
      "entity_id": null
    }
  ]
}